About The Study

Age-related macular degeneration (AMD) is the leading cause of severe and irreversible vision loss in people over the age of 65 in the United States (US) and in western countries. More than 1.6 million people in the US currently have one or both eyes affected by advanced AMD, and more than 230,000 people in the US are believed to be legally blind due to AMD.

The purpose of this study is for researchers to learn about the safety and efficacy (how effective the investigational study drug is) of the investigational study drug when compared with standard-of-care treatment in subjects with neovascular “wet” age-related macular degeneration (wAMD) who have not received treatment before (i.e., treatment naïve).

Participants in this study must:

  • be at least 50 years of age
  • have newly diagnosed wAMD
  • have never received treatment for age-related macular degeneration (AMD), other than dietary supplements or vitamins